Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | DEGS1 | O15121 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2318170 | 0.88 | ALDH1A1 (0.55) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL2318241 | 0.83 | NPY5R (0.48) | SMN1; SMN2DEGS1LMNAUSP30 | |
| SCHEMBL2319049 | 0.82 | EPHX2 (0.47) | RAB9AALDH1A1SMN1; SMN2NPC1LMNA | |
| SCHEMBL31241006 | 0.80 | RAB9A (0.68) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL2317080 | 0.80 | RAB9A (0.56) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL31241140 | 0.78 | RAB9A (0.73) | RAB9AALDH1A1SMN1; SMN2NPC1POLB | |
| SCHEMBL2417326 | 0.73 | EPHX2 (0.44) | SMN1; SMN2DEGS1LMNAUSP30EPHX2 | |
| SCHEMBL2318660 | 0.72 | NPY5R (0.52) | DEGS1USP30 | |
| SCHEMBL2321999 | 0.71 | USP30 (0.50) | ALDH1A1SMN1; SMN2POLBTSHRDEGS1 | |
| SCHEMBL31241020 | 0.71 | RAB9A (0.65) | RAB9AALDH1A1SMN1; SMN2NPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2011-09-22 | — | — | US | disclosed |
| EP-2352730-A2 | BIOLOGICALLY ACTIVE AMIDES | H. Lundbeck A/S (DK) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010053861-A2 | BIOLOGICALLY ACTIVE AMIDES | H. LUNDBECK A/S (DK) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230497-A1 | BIOLOGICALLY ACTIVE AMIDES | NPY5R, NPY1R, NPY2R | RAB9A 3184/4885ALDH1A1 3024/4885SMN1; SMN2 1836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.